THE ANALYSIS OF L1 GENE VARIABILITY OF HUMAN PAPILLOMA VIRUS TYPE 16 IN OUR POPULATION

  • Filip Milošević Institut za mikrobiologiju i imunologiju, Medicinski fakultet Univerziteta u Beogradu, Beograd
  • Nina Gatarić Univerzitet u Beogradu, Medicinski fakultet, Institut za fiziologiju "Rihard Burijan", Beograd, Srbija
  • Aleksandra Knezevic Institut za mikrobiologiju i imunologiju, Medicinski fakultet Univerziteta u Beogradu
Keywords: Human papilloma virus, HPV16, gene, phylogenetic analysis

Abstract


Introduction: Human papilloma viruses (HPV) have been identified as a major etiological factor in the pathogenesis of cervical cancer. High-risk type HPV16 has the greatest medical significance. Based on the differences in the nucleotide sequence of the type 16 genome, the existence of 16 variants of this type with different geographical distribution has been shown.

Aim: Examination of the nucleotide sequence variability of the L1 gene presented in HPV16 variants in our territory.

Material and methods: The paper includes 37 sequences of HPV16 L1 genes taken from the database of the Institute of Microbiology and Immunology of the Medical Faculty, University of Belgrade. The sequences were compared with the reference sequences of the HPV16 variants and the construction of the phylogenetic tree was done using the MEGA (Molecular Evolutionary Genetics Analysis, version X) software package.

Results: Out of the 37 HPV16 L1 gene sequences analyzed, 23 were grouped with European variants. Other isolates were grouped with non-European HPV16 variants. The nucleotide distance was less than 1%, that is, at the level of subvariants.

Conclusion: The results of this study indicate that the European variants of the HPV16 virus are the most common in our population, but they also indicate the presence of non-European variants. Further analysis is necessary in order to monitor the circulation of HPV16 variants in our population.

Keywords: Human papilloma virus, HPV16, L1 gene, phylogenetic analysis

References


  1. Knežević A, 2019. Medicinska mikrobiologija. 1st ed. Beograd: Medicinski fakultet Univerziteta u Beogradu, pp.513-518.

  2. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-3890.

  3. Boulet G, Horvath C, Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. The International Journal of Biochemistry & Cell Biology. 2007;39(11):2006-2011.

  4. Forman D, de Martel C, Lacey C, Soerjomataram I, Lortet-Tieulent J, Bruni L et al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine. 2012;30:F12-F23.

  5. Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443-8450.

  6. Winer R, Feng Q, Hughes J, O’Reilly S, Kiviat N, Koutsky L. Risk of Female Human Papillomavirus Acquisition Associated with First Male Sex Partner. The Journal of Infectious Diseases. 2008;197(2):279-282.

  7. Mühr L, Eklund C, Dillner J. Towards quality and order in human papillomavirus research. Virology. 2018;519:74-76.

  8. de Villiers E. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1-2):2-10.

  9. zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 2009;384(2):260-265.

  10. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F et al. A review of human carcinogens—Part B: biological agents. The Lancet Oncology. 2009;10(4):321-322.

  11. Serrano B, Brotons M, Bosch F, Bruni L. Epidemiology and burden of HPV-related disease. Best Practice & Research Clinical Obstetrics & Gynaecology. 2018;47:14-26.

  12. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer. 2017;141(4):664-670.

  13. 13. Bello B, Spinillo A, Alberizzi P, Cesari S, Gardella B, D'Ambrosio G et al. Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions. Journal of Medical Virology. 2009;81(4):703-712.

  14. Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. JNCI Journal of the National Cancer Institute. 1995;87(11):796-802.

  15. Li N, Franceschi S, Howell-Jones R, Snijders P, Clifford G. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International Journal of Cancer. 2010;128(4):927-935.

  16. Zehender G, Frati E, Martinelli M, Bianchi S, Amendola A, Ebranati E et al. Dating the origin and dispersal of Human Papillomavirus type 16 on the basis of ancestral human migrations. Infection, Genetics and Evolution. 2016;39:258-264.

  17. de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology. 2010;11(11):1048-1056.

  18. Bernard H, Burk R, Chen Z, van Doorslaer K, Hausen H, de Villiers E. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70-79.

  19. Burk R, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1-2):232-243.

  20. Mirabello L, Clarke M, Nelson C, Dean M, Wentzensen N, Yeager M et al. The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses. 2018;10(2):80.

  21. Cornet I, Gheit T, Iannacone M, Vignat J, Sylla B, Del Mistro A et al. HPV16 genetic variation and the development of cervical cancer worldwide. British Journal of Cancer. 2012;108(1):240-244.

  22. Cornet I, Gheit T, Franceschi S, Vignat J, Burk R, Sylla B et al. Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. Journal of Virology. 2012;86(12):6855-6861.

  23. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2014;136(5):E359-E386.

  24. Park J, Shin S, Kim E, Kim J, Kim Y, Oh S et al. Association of human papillomavirus type 16 and its genetic variants with cervical lesion in Korea. APMIS. 2016;124(11):950-957.

  25. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A et al. Human Papillomavirus Type 16 Variants and Risk of Cervical Cancer. JNCI Journal of the National Cancer Institute. 2001;93(4):315-318.

  26. Rader J, Tsaih S, Fullin D, Murray M, Iden M, Zimmermann M et al. Genetic variations in human papillomavirus and cervical cancer outcomes. International Journal of Cancer. 2019;144(9):2206-2214.

  27. Clifford G, Tenet V, Georges D, Alemany L, Pavón M, Chen Z et al. Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Research. 2019;7:67-74.

  28. Bernard H. Coevolution of papiliomaviruses with human populations. Trends in Microbiology. 1994;2(4):140-143.

  29. Kovačević G, Milošević V, Knežević P, Knežević A, Knežević I, Radovanov J et al. Prevalence of oncogenic Human papillomavirus and genetic diversity in the L1 gene of HPV16 HPV 18 HPV31 and HPV33 found in women from Vojvodina Province Serbia. Biologicals. 2019;58:57-63.

  30. Jendoubi-Ferchichi M, Satouri L, Ghoul F, Malek-Mellouli M, Derbal A, Makni M et al. Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions. Asian Pacific Journal of Cancer Prevention. 2018;19(12):3361-3366.

Published
2023/02/06
Issue
Vol. 73 No. 4 (2022): Medicinski podmladak
Section
Original Scientific Paper